Oligosecretory monoclonal gammopathy with renal involvement


Cite item

Full Text

Abstract

The article deals with the so-called monoclonal gammopathy of undetermined significance (MGUS), which is being actively explored in the world and has been recently investigated in Russia. It indicates the principles of identifying the phenotypes of MGUS and criteria for assessing the risk of its progression to cancer. There is an update on the possible involvement of monoclonal proteins in the pathogenesis of certain non-neoplastic kidney diseases, renal injuries in particular. The paper gives their classification and enumerates differential diagnostic techniques, including the Freelite method, a highly sensitive one to determine free light chains (FLC), prognostic criteria, and approaches to treating each separate form in relation to the phenotype of a monoclonal protein. The authors present their own data on detection rates for MGUS at a multidisciplinary hospital and a clinical case of MGUS-associated membranoproliferative glomerulonephritis, by justifying a treatment regimen containing bortezomib (velcade).

References

  1. Kyle R, Rajkumar S Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol. 2007;139(5):730-743. doi: 10.1111/j.1365-2141.2007.06873.x
  2. Zingone A, Kuehl M Pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and progression to multiple myeloma. Semin Hematol. 2011;48(1):4-12. doi: 10.1053/j.seminhematol.2010.11.003
  3. Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson S, Caers J,Usmani S, Lahuerta J, Johnsen H, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle R, Anderson K, Durie B, Miguel J International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):538-548. doi: 10.1016/S1470-2045(14)70442-5
  4. Hutchison C, Basnayake K, Cockwell P Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol. 2009;5:621-627. doi: 10.1038/nrneph.2009.151
  5. Parry H, Pratt G, Hutchison C Monoclonal gammopathy of undetermined significance: an update for nephrologists. Adv Chronic Kidney Dis. 2012;19(5):291-296. doi: 10.1053/j.ackd.2012.07.006
  6. Katzmann J, Clark R, Abraham R, Bryant S, Lymp J, Bradwell A, Kyle R Serum Reference Intervals and Diagnostic Ranges for Free _ and Free Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains. Clinical Chemistry. 2002;48(9):1437-1444.
  7. Katzmann J, Kyle R, Benson J, Larson D, Snyder M, Lust J, Rajkumar S, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517-1522. doi: 10.1373/clinchem.2009.126664
  8. Gertz M. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:181-186. doi: 10.1002/ajh.21934
  9. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS): A retrospective population-based cohort study. Lancet. 2010;375(9727):1721-1728. doi: 10.1016/S0140-6736(10)60482-5
  10. Kapoulas S, Raptis V, Papaioannou M New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrol Ther. 2015;11(3):135-143. doi: 10.1016/j.nephro.2014.12.005
  11. Heher E, Goes N, Spitzer T, Raje N, Humphreys B, Anderson K, Richardson P Kidney disease associated with plasma cell dyscrasias. Blood. 2010:116(9):1397-1404. doi: 10.1182/blood-2010-03-258608
  12. Solomon A, Weiss D, Kattine A Nephrotoxic potential of Bence Jones proteins. N Engl J Med. 1991;324:1845-1851. doi: 10.1056/NEJM199106273242603
  13. Basnayake K, Stringer S, Hutchison C, Cockwell P The biology of immunoglobulin free light chains and kidney injury. Kidney International. 2011;79:1289-1301. doi: 10.1038/ki.2011.94
  14. Lorenz E, Sethi S, Leung N, Dispenzieri A, Fervenza F, Cosio F Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney International. 2010;77:721-728. doi: 10.1038/ki.2010.1
  15. Nasr S, Sethi S, Cornell L, Fidler M, Boelkins M, Fervenza F, Cosio F, D’Agati F Proliferative Glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol. 2011;6(1):122-132. doi: 10.2215/CJN.05750710
  16. Hassoun H, Flombaum C, D’Agati V, Rafferty B, Cohen A, Klimek V, Boruchov A, Kewalramani T, Reich L, Nimer S, Comenzo R High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant. 2008;42(6):405-412. doi: 10.1038/bmt.2008.179
  17. Fermand J-P, Bridoux F, Kyle R, Kastritis E, Weiss B, Cook M, Drayson M, Dispenzieri A, Leung N et al How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583-3590. doi: 10.1182/blood-2013-05-495929
  18. Sethi S, Zand L, Leung N, Smith R, Jevremonic D, Herrmann S, Fervenza F. Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy. Clin J Am Soc Nephrol. 2010;5:770-782. doi: 10.2215/CJN.06760909
  19. Nasr S, Satoskar A, Markowitz G, Valeri A, Appel G, Stokes M, Nadasdy T, D’Agat V Proliferative Glomerulonephritis with Monoclonal IgG Deposits. J Am Soc Nephrol. 2009;20:2055-2064. doi: 10.1681/ASN.2009010110
  20. Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc. 2013;88(11):1284-1293. doi: 10.1016/j.mayocp.2013.08.002
  21. Bridoux F, Desport E, Fremeaux-Bacchi V et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9):2165-2174. doi: 10.2215/CJN.06180710
  22. Zand L, Kattah A, Fervenza F, Smith R, Nasr S, Zhang Y, Vrana J, Leung N, Cornell L, Sethi S C3 Glomerulonephritis associated with Monoclonal Gammopathy. AmJKidneyDis. 2013;62(3):506-514. doi: 10.1053/j.ajkd.2013.02.370

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies